|
1
|
Villanueva A: Hepatocellular carcinoma. N
Engl J Med. 380:1450–1462. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Llovet JM, Kelley RK, Villanueva A, Singal
AG, Pikarsky E, Roayaie S, Lencioni R, Koike K, Zucman-Rossi J and
Finn RS: Hepatocellular carcinoma. Nat Rev Dis Primers. 7:62021.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lencioni R, de Baere T, Soulen MC, Rilling
WS and Geschwind JFH: Lipiodol transarterial chemoembolization for
hepatocellular carcinoma: A systematic review of efficacy and
safety data. Hepatology. 64:106–116. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Llovet JM and Bruix J: Systematic review
of randomized trials for unresectable hepatocellular carcinoma:
Chemoembolization improves survival. Hepatology. 37:429–442. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Murata S, Mine T, Sugihara F, Yasui D,
Yamaguchi H, Ueda T, Onozawa S and Kumita S: Interventional
treatment for unresectable hepatocellular carcinoma. World J
Gastroenterol. 20:13453–13465. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Murakami T and Tsurusaki M: Hypervascular
benign and malignant liver tumors that require differentiation from
hepatocellular carcinoma: Key points of imaging diagnosis. Liver
Cancer. 3:85–96. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tsurusaki M and Murakami T: Surgical and
locoregional therapy of HCC: TACE. Liver Cancer. 4:165–175. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chen X, Tang FR, Arfuso F, Cai WQ, Ma Z,
Yang J and Sethi G: The emerging role of long non-coding RNAs in
the metastasis of hepatocellular carcinoma. Biomolecules.
10:662019. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ji J, Gu J, Wu JZ, Yang W, Shi HB, Liu S
and Zhou WZ: The ‘six-and-twelve’ score for recurrent HCC patients
receiving TACE: Does it still work? Cardiovasc Intervent Radiol.
44:720–727. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bruix J, Sala M and Llovet JM:
Chemoembolization for hepatocellular carcinoma. Gastroenterology.
127 (5 Suppl 1):S179–S188. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Llovet JM, Real MI, Montaña X, Planas R,
Coll S, Aponte J, Ayuso C, Sala M, Muchart J, Solà R, et al:
Arterial embolisation or chemoembolisation versus symptomatic
treatment in patients with unresectable hepatocellular carcinoma: A
randomised controlled trial. Lancet. 359:1734–1739. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tsuchiya N, Sawada Y, Endo I, Saito K,
Uemura Y and Nakatsura T: Biomarkers for the early diagnosis of
hepatocellular carcinoma. World J Gastroenterol. 21:10573–10583.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Luo P, Wu S, Yu Y, Ming X, Li S, Zuo X and
Tu J: Current status and perspective biomarkers in AFP negative
HCC: Towards screening for and diagnosing hepatocellular carcinoma
at an earlier stage. Pathol Oncol Res. 26:599–603. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wang T and Zhang KH: New blood biomarkers
for the diagnosis of AFP-negative hepatocellular carcinoma. Front
Oncol. 10:13162020. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Liebman HA, Furie BC, Tong MJ, Blanchard
RA, Lo KJ, Lee SD, Coleman MS and Furie B: Des-gamma-carboxy
(abnormal) prothrombin as a serum marker of primary hepatocellular
carcinoma. N Engl J Med. 310:1427–1431. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Inagaki Y, Tang W, Makuuchi M, Hasegawa K,
Sugawara Y and Kokudo N: Clinical and molecular insights into the
hepatocellular carcinoma tumour marker des-γ-carboxyprothrombin.
Liver Int. 31:22–35. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Verslype C, Rosmorduc O and Rougier P;
ESMO Guidelines Working Group, : Hepatocellular carcinoma:
ESMO-ESDO clinical practice guidelines for diagnosis, treatment and
follow-up. Ann Oncol. 23 (Suppl 7):vii41–vii48. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Oken MM, Creech RH, Tormey DC, Horton J,
Davis TE, McFadden ET and Carbone PP: Toxicity and response
criteria of the eastern cooperative oncology group. Am J Clin
Oncol. 5:649–655. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Seldinger SI: Catheter replacement of the
needle in percutaneous arteriography; a new technique. Acta Radiol.
39:368–376. 1953. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhou J, Sun H, Wang Z, Cong W, Wang J,
Zeng M, Zhou W, Bie P, Liu L, Wen T, et al: Guidelines for the
diagnosis and treatment of hepatocellular carcinoma (2019 edition).
Liver Cancer. 9:682–720. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Laird BJ, Kaasa S, McMillan DC, Fallon MT,
Hjermstad MJ, Fayers P and Klepstad P: Prognostic factors in
patients with advanced cancer: A comparison of clinicopathological
factors and the development of an inflammation-based prognostic
system. Clin Cancer Res. 19:5456–5464. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Barrett T, Wilhite SE, Ledoux P,
Evangelista C, Kim IF, Tomashevsky M, Marshall KA, Phillippy KH,
Sherman PM, Holko M, et al: NCBI GEO: Archive for functional
genomics data sets-update. Nucleic Acids Res. 41:(Database Issue).
D991–D995. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Murakami Y, Kubo S, Tamori A, Itami S,
Kawamura E, Iwaisako K, Ikeda K, Kawada N, Ochiya T and Taguchi YH:
Comprehensive analysis of transcriptome and metabolome analysis in
intrahepatic cholangiocarcinoma and hepatocellular carcinoma. Sci
Rep. 5:162942015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Diboun I, Wernisch L, Orengo CA and
Koltzenburg M: Microarray analysis after RNA amplification can
detect pronounced differences in gene expression using limma. BMC
Genomics. 7:2522006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ashburner M, Ball CA, Blake JA, Botstein
D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT,
et al: Gene ontology: Tool for the unification of biology. The gene
ontology consortium. Nat Genet. 25:25–29. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Szklarczyk D, Morris JH, Cook H, Kuhn M,
Wyder S, Simonovic M, Santos A, Doncheva NT, Roth A, Bork P, et al:
The STRING database in 2017: Quality-controlled protein-protein
association networks, made broadly accessible. Nucleic Acids Res.
45(D1): D362–D368. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chin CH, Chen SH, Wu HH, Ho CW, Ko MT and
Lin CY: cytoHubba: Identifying hub objects and sub-networks from
complex interactome. BMC Syst Biol. 8 (Suppl 4):S112014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Bader GD and Hogue CWV: An automated
method for finding molecular complexes in large protein interaction
networks. BMC Bioinformatics. 4:22003. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lee YK, Kim SU, Kim DY, Ahn SH, Lee KH,
Lee DY, Han KH, Chon CY and Park JY: Prognostic value of
α-fetoprotein and des-γ-carboxy prothrombin responses in patients
with hepatocellular carcinoma treated with transarterial
chemoembolization. BMC Cancer. 13:52013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hiraoka A, Ishimaru Y, Kawasaki H, Aibiki
T, Okudaira T, Toshimori A, Kawamura T, Yamago H, Nakahara H, Suga
Y, et al: Tumor markers AFP, AFP-L3, and DCP in hepatocellular
carcinoma refractory to transcatheter arterial chemoembolization.
Oncology. 89:167–174. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kokudo N, Hasegawa K, Akahane M, Igaki H,
Izumi N, Ichida T, Uemoto S, Kaneko S, Kawasaki S, Ku Y, et al:
Evidence-based clinical practice guidelines for hepatocellular
carcinoma: The Japan society of hepatology 2013 update (3rd JSH-HCC
guidelines). Hepatol Res. 45:2015. View Article : Google Scholar
|
|
32
|
Omata M, Lesmana LA, Tateishi R, Chen PJ,
Lin SM, Yoshida H, Kudo M, Lee JM, Choi BI, Poon RT, et al: Asian
pacific association for the study of the liver consensus
recommendations on hepatocellular carcinoma. Hepatol Int.
4:439–474. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Saito M, Seo Y, Yano Y, Miki A, Yoshida M
and Azuma T: A high value of serum des-γ-carboxy prothrombin before
hepatocellular carcinoma treatment can be associated with long-term
liver dysfunction after treatment. J Gastroenterol. 47:1134–1142.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kinugasa H, Nouso K, Takeuchi Y, Yasunaka
T, Onishi H, Nakamura S, Shiraha H, Kuwaki K, Hagihara H, Ikeda F,
et al: Risk factors for recurrence after transarterial
chemoembolization for early-stage hepatocellular carcinoma. J
Gastroenterol. 47:421–426. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Payancé A, Dioguardi Burgio M, Peoc'h K,
Achahboun M, Albuquerque M, Devictor J, Chor H, Manceau H, Soubrane
O, Durand F, et al: Biological response under treatment and
prognostic value of protein induced by vitamin K absence or
antagonist-II in a French cohort of patients with hepatocellular
carcinoma. Eur J Gastroenterol Hepatol. 32:1364–1372. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Yamamoto K, Imamura H, Matsuyama Y,
Hasegawa K, Beck Y, Sugawara Y, Makuuchi M and Kokudo N:
Significance of alpha-fetoprotein and des-gamma-carboxy prothrombin
in patients with hepatocellular carcinoma undergoing hepatectomy.
Ann Surg Oncol. 16:2795–2804. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Vogelstein B, Papadopoulos N, Velculescu
VE, Zhou S, Diaz LA Jr and Kinzler KW: Cancer genome landscapes.
Science. 339:1546–1558. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Guo Y, Bao Y, Ma M and Yang W:
Identification of key candidate genes and pathways in colorectal
cancer by integrated bioinformatical analysis. Int J Mol Sci.
18:7222017. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Warner JR and McIntosh KB: How common are
extraribosomal functions of ribosomal proteins? Mol Cell. 34:3–11.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wang Y, Huang JW, Castella M, Huntsman DG
and Taniguchi T: p53 is positively regulated by miR-542-3p. Cancer
Res. 74:3218–3227. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Zhou C, Sun J, Zheng Z, Weng J, Atyah M,
Zhou Q, Chen W, Zhang Y, Huang J, Yin Y, et al: High RPS11 level in
hepatocellular carcinoma associates with poor prognosis after
curative resection. Ann Transl Med. 8:4662020. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Zhou C, Weng J, Liu C, Zhou Q, Chen W, Hsu
JL, Sun J, Atyah M, Xu Y, Shi Y, et al: High RPS3A expression
correlates with low tumor immune cell infiltration and unfavorable
prognosis in hepatocellular carcinoma patients. Am J Cancer Res.
10:2768–2784. 2020.PubMed/NCBI
|
